FDA Sends Warning Letters to More Than 50 GLP 1 Compounders and Manufacturers Wilson Sonsini Peptide Therapy Orange County Blueline Wellness Blueline Wellness FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling BPC 157 and the Difference Between an Evidence Gap and a Cover Up: What the entire human evidence base actually looks like, and the questions to ask next. WellFounded Founders Health & FDA to weigh easing limits on unproven peptides promoted by RFK Jr.